The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ICML 2019 | CLL12: ibrutinib monotherapy upfront, a potential competitor for ‘watch-and-wait’?
Michael Hallek
• 19 Jun 2019
Michael Hallek, MD, PhD, University of Cologne, Cologne, Germany, discusses the CLL12 trial (NCT02863718) of ibrutinib compared to a placebo in asymptomatic, untreated chronic lymphocytic leukemia (CLL). This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.
